Biomedical covered time and dynamic risk
At week 24, the structured survey to assess the use of PrEP or PEP and HIV risk over the prior 6 months was completed by 91% (554/612) participants overall: 94% ANC participants, 87% OPD participants and 90% community participants. Mean biomedical covered time (proportion of 24‐week follow‐up during which a participant reported the use of either PrEP or PEP) was 80% in ANC (median 100%, Q1: 67%, Q3 100%), 60% in OPD (median 67%, Q1 33%, Q3 100%) and 32% in the community setting (median 0%, Q1 0%, Q3 67%). While all participants reported current or anticipated HIV risk at baseline, self‐reported HIV risk experienced, assessed retrospectively at week 24, varied over time (Figure Heat maps of use of biomedical prevention by HIV risk over the 24‐week follow‐up period in the ANC (top), OPD (middle) and community (bottom) settings. Each row corresponds to a participant, and each column to a follow‐up month. Green represents HIV risk with biomedical coverage (i.e. use of oral PrEP or PEP); red represents HIV risk without biomedical coverage; yellow represents no HIV risk but with biomedical coverage; and blue represents no HIV risk and no coverage. Abbreviations: ANC, antenatal clinics; OPD, outpatient departments.